[Results of a phase I-II clinical trial of Emoxyl, a novel antineoplastic anthracycline].
Emoxyl (ruboxyl) is a product of chemical modification of daunorubicin mediated by a stable free radical. The drug was given to 63 patients with different malignancies stages I-II. Inhibition of hemopoiesis (leukopenia and thrombocytopenia) was identified as the dose-limiting toxicity level. Alopecia or cardiotoxicity were not reported. A daily single dose of 100 mg/m2, 5 days, repeated in cycles after 3 weeks, proved the safest and most effective. Out of 55 cases evaluated for immediate effect, complete remission (breast cancer, small-cell cancer of the lung, Kaposi's sarcoma)--3; partial remission (breast cancer--2; non-Hodgkin's lymphoma--1)--3, and stabilization--26.